Big Pharma backs clinical trials industry in Quebec

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/dk_photos)
(Image: Getty/dk_photos)

Related tags Glaxosmithkline Pfizer AbbVie Takeda Novartis Merck Servier Roche Clinical trials

Pharma giants including Pfizer, GSK, and Abbvie, renew their financial commitment to the early-stage clinical research in Quebec, Canada.

Catalis Québec is a is a public-private partnership developing tools to support early-stage clinical research. The organization “has the mandate of promoting Quebec's expertise in conducting early-stage clinical trials,”​ said Danika Laberge, general director of Catalis Quebec.

Catalis has partnerships with five Quebec-based health and social service organizations and eight pharmaceutical companies, including GlaxoSmithKline, Pfizer, AbbVie, Takeda, Novartis, Merck, Servier, and Roche, which have invested nearly CAD 1.6m ($1.19m) in the Catalis initiative since 2017.

The pharma companies this week announced renewed financial commitments to Catalis during the 2019 BIO International Convention.

“Catalis Quebec acts as a coordination office by rallying behind the efforts of its partners in order to stimulate private investment and promote excellence in the conduct of phase I, II and II-III clinical trials,”​ explained Laberge.

“Our projects benefit all life science research stakeholders and have positive economic and social impacts for Quebec and Canada,” ​she told us.

Projects announced so far this year include the development of standard operating procedures for ethical reviews of clinical research, an automated performance reporting tool, and a new system to manage and approve multicenter research projects.

Per there are more than 1,400 studies currently underway in Canada. Laberge described Quebec as a preferred location “for its medical and scientific expertise, state-of-the-art infrastructure and research-friendly economic and regulatory environment,”​ said Laberge.

“Quebec has everything it needs to meet the growing demand,”​ she added, citing a $10bn investment from the Government of Quebec to modernize its health care facilities.

Said Laberge, “Several institutions have established Phase I clinical research units, which provides an environment conducive to early clinical trials.”

Related topics Clinical Development Phase I-II

Related news

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us


View more